JTEC

JTEC EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of JTEC (3446.T) as of Oct 24, 2026 is 72.88 M JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 113.82 M JPY — a change of -35.97% (lower).

EBITDA

72.88 MJPY

YoY

-35.97%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of JTEC is 2026 72.88 M JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of JTEC was 2025 113.82 M JPY. It decreases by -35.97% lower compared to the previous year.

The JTEC EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
166.43 M JPY
Jan 1, 2020
34.01 M JPY
Jan 1, 2021
-244.47 M JPY
Jan 1, 2022
-71.22 M JPY
Jan 1, 2023
306.67 M JPY
Jan 1, 2024
285.84 M JPY
Jan 1, 2025
113.82 M JPY
Jan 1, 2026
72.88 M JPY
The JTEC EBITDA history
YEAREBITDAYoY
72.88 MJPY-35.97%
113.82 MJPY-60.18%
285.84 MJPY-6.79%
306.67 MJPY-530.59%
-71.22 MJPY-70.87%
-244.47 MJPY-818.76%
34.01 MJPY-79.56%
166.43 MJPY+96.49%
84.70 MJPY-34.91%
130.12 MJPY+71.14%
76.03 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JTEC Stock analysis

What does JTEC do? JTEC Corp generates revenue through its two business segments. The Optical segment sells X-ray nano-collecting mirrors for synchrotron radiation and X-ray free electron laser facilities, targeting research institutions and companies in basic and industrial research. The Life Science and Equipment Development segment offers automatic cell culture devices and other automation equipment, primarily to medical, biotechnology sectors, and research institutes. Both segments develop and sell proprietary products alongside outsourced manufacturing services. The Optical segment focuses on specialized mirrors for advanced analyzers used in scientific research, while the Life Science segment provides automation solutions for cell culture processes. These products serve a range of applications from fundamental research to industrial uses, with sales directed to research organizations and industry partners in biotechnology and medical fields. JTEC Corp's revenue streams include direct sales of X-ray mirrors and cell culture devices, as well as outsourced manufacturing for proprietary products. The company's target customers are research institutions, biotechnology firms, and medical companies requiring advanced automation and precision equipment for their operations. JTEC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JTEC stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of JTEC is 72.88 M JPY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of JTEC changed from 113.82 M JPY to 72.88 M JPY, representing a -35.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) JTEC since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JTEC historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — JTEC

All Key Metrics — JTEC